Join
Live feed
·
PRReleasevia Quantisnow
CRISPR Therapeutics AG logo

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

ByQuantisnow·Wall Street's wire, on your screen.
CRSP· CRISPR Therapeutics AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRSP (CRISPR Therapeutics AG) and more on Quantisnow.